Approved and investigational Ebola prophylaxis

Introduction to the Orthoebolavirus Landscape

Ebola virus disease (EVD) is a rare but highly lethal hemorrhagic fever caused by enveloped, single-stranded RNA viruses within the Orthoebolavirus genus of the Filoviridae family ¹². Since the pathogen was first identified in 1976 during two simultaneous outbreaks - one in Yambuku, Democratic Republic of the Congo (DRC), and the other in Nzara, South Sudan - EVD has remained a severe and recurrent public health threat across the African continent ²³. The disease is characterized by extreme virulence, with historical case fatality rates ranging from 25% to 90%, depending heavily on the specific viral strain, the patient's viral load at presentation, and the availability of advanced medical interventions ²⁴.

The genus comprises several distinct species known to cause significant disease in human populations, with the most epidemiologically critical being Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV), and Bundibugyo ebolavirus (BDBV) ²⁵. For decades, the global management of EVD relied entirely on classical epidemiological containment: isolating infected individuals, tracking transmission chains, and providing basic supportive care in austere environments ⁴. However, the catastrophic West African EBOV epidemic of 2014 - 2016, which resulted in over 28,000 confirmed infections and more than 11,000 deaths, catalyzed an unprecedented acceleration in global biopharmaceutical research and development ⁶⁷. This intense, multi-national scientific effort successfully yielded the first approved vaccines and monoclonal antibody (mAb) therapeutics, fundamentally altering the prophylactic and therapeutic landscape for Zaire ebolavirus ²⁴.

Despite these monumental scientific advancements, the prophylactic arsenal remains highly asymmetric across the Orthoebolavirus genus. While robust, regulatory-approved countermeasures exist for EBOV, there are currently no licensed vaccines or targeted therapeutics available for SUDV or BDBV outside of experimental clinical trial frameworks ²⁷. This gap in the medical toolkit has profound implications for regional health security. Consequently, contemporary Ebola prevention cannot rely on vaccination alone; it demands a highly integrated strategy encompassing active immunization, experimental post-exposure prophylaxis (PEP), optimized clinical supportive care, and rigorously adapted socio-cultural infection prevention and control (IPC) protocols.

Countermeasure Disparity Across Orthoebolavirus Species

The medical countermeasure landscape for Orthoebolaviruses reveals robust approved options for Zaire ebolavirus, while Sudan and Bundibugyo viruses rely strictly on investigational products and supportive care ^257891011.

Zaire Ebolavirus Approved Vaccines

The global prophylactic strategy against Zaire ebolavirus currently relies on two primary vaccine regimens, both of which have been prequalified by the World Health Organization (WHO) and integrated into global emergency stockpiles ⁵¹². These vaccines utilize distinct viral vector platforms to deliver the EBOV envelope glycoprotein (GP) antigen, stimulating both humoral and cellular immune responses ⁸.

Recombinant Vesicular Stomatitis Virus Vaccine (Ervebo)

Developed initially by the Public Health Agency of Canada and subsequently licensed to Merck Sharp & Dohme, rVSV-ZEBOV-GP (marketed under the trade name Ervebo) was the first Ebola vaccine to receive regulatory approval from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in late 2019 ¹⁹¹³. It is currently the primary vaccine utilized for rapid outbreak response worldwide.

Mechanism and Composition Ervebo is a live, attenuated, recombinant vesicular stomatitis virus (rVSV)-based chimeric-vector vaccine ⁸¹³. In its genetic construction, the native VSV envelope glycoprotein has been completely deleted (ΔG) and replaced with the envelope glycoprotein (GP) of the Zaire ebolavirus (specifically the Kikwit variant) ⁸⁹¹³. Because it is a replication-competent live vaccine, it mimics natural viral infection sufficiently to elicit rapid and robust immunity following a single 1.0 mL intramuscular administration ⁸¹⁴¹⁵. The vaccine vector delivers the antigen specifically to target cells, inducing long-lived immunological memory ⁸.

Clinical Efficacy and Immunogenicity Clinical and observational data indicate exceptionally high efficacy for Ervebo. In a major phase 3 cluster-randomized ring vaccination trial conducted during the West African outbreak, the vaccine demonstrated 100% efficacy in preventing EVD cases among individuals who had a symptom onset greater than ten days post-vaccination ⁹. In the comparison between the "immediate" vaccination arm (2,108 individuals) and the 21-day "delayed" vaccination arm (1,429 individuals), zero cases were observed in the immediate cohort after the ten-day immunological window, compared to ten cases in the delayed cohort ⁹.

Further real-world observational data collected during the 2018 - 2020 Kivu EVD epidemic in the DRC indicated an overall field vaccine effectiveness of 84% (95% CI: 88 - 97%) against symptomatic EVD onset ⁹¹²¹⁶. While the exact duration of clinical protection remains the subject of ongoing longitudinal studies, EBOV-specific binding antibodies have been shown to remain at elevated levels without evidence of waning for at least five years post-vaccination ¹⁶.

Logistics and Cold Chain Requirements One of the primary operational challenges associated with Ervebo is its highly stringent cold chain requirements. The vaccine must be stored and transported frozen at ultra-low temperatures ranging from -80°C to -60°C (-112°F to -76°F) to maintain its shelf life, which is licensed for three to five years depending on the regulatory jurisdiction ^1171819.

The thawing and preparation processes are highly specific. The vaccine vial must be thawed at room temperature until no visible ice remains, a process that typically takes 10 to 15 minutes ¹⁹²⁰. Regulatory guidelines explicitly prohibit thawing the vial in a refrigerator, as the vaccine is highly sensitive to slow thawing processes, which can degrade the live vector ¹⁷¹⁹²⁰. Once thawed, Ervebo cannot be refrozen ¹⁷¹⁹. However, it demonstrates acceptable in-use stability; if not administered immediately upon thawing, the vaccine can be stored for up to 14 days when strictly maintained between 2°C and 8°C (35.6°F to 46.4°F), or for a maximum of four hours at controlled room temperature (up to 25°C or 77°F) while protected from light ¹⁵¹⁷¹⁹.

Safety Profile and Viral Shedding Ervebo is indicated for the active immunization of individuals aged 12 months and older ¹³¹⁸. Because the vaccine contains a replication-competent live virus, there is a theoretical potential for the transmission of the vaccine virus to close contacts. Clinical studies have detected vaccine virus RNA via rRT-PCR in the blood and saliva of vaccinated persons up to 14 days post-vaccination, in urine up to 7 days post-vaccination, and in synovial fluid and skin vesicles up to 20 days post-vaccination ¹⁵. However, actual secondary transmission causing illness has not been documented.

Furthermore, the concurrent administration of antiviral medications, interferons, or immune globulins is strongly discouraged. Administration of blood products or immune globulins within three months prior to, or one month following, Ervebo administration may neutralize the live vector, interfering with viral replication and severely impairing the expected immune response ¹⁴¹⁸²⁰. The vaccine must not be mixed in the same syringe with any other medicinal products ¹⁵²⁰.

Adenovirus and Modified Vaccinia Ankara Regimen (Zabdeno/Mvabea)

The second approved prophylactic regimen is a two-dose heterologous prime-boost strategy developed collaboratively by Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bavarian Nordic ⁷⁸. The regimen consists of a primary dose of Zabdeno (Ad26.ZEBOV) followed approximately eight weeks (56 days) later by a booster dose of Mvabea (MVA-BN-Filo) ⁷⁸²¹.

Mechanism and Composition In stark contrast to Ervebo, both components of the Zabdeno/Mvabea regimen utilize replication-deficient viral vectors, ensuring that the vectors cannot replicate within human host cells, thereby eliminating the risk of vaccine virus shedding ⁷⁸. * Zabdeno (Prime): This component is derived from human adenovirus serotype 26 (Ad26), which has been genetically modified to express the EBOV Mayinga variant glycoprotein in place of the replication-essential adenovirus early 1 region ⁸⁹. * Mvabea (Boost): This component utilizes the Modified Vaccinia virus Ankara (MVA) platform, encoding glycoproteins from multiple filoviruses, including EBOV, Sudan virus (SUDV), Marburg virus (MARV), and the Taï Forest virus nucleoprotein ⁷⁸. Despite this multivalent design intended to eventually offer pan-filovirus protection, protective efficacy has currently only been formally bridged and established for Zaire ebolavirus ⁷⁸.

Efficacy and Immunogenicity Dynamics Because the full heterologous regimen requires an eight-week interval between the prime and boost doses, it is inherently unsuitable for acute outbreak response scenarios where immediate immunity (such as in reactive ring vaccination) is required ⁸⁹. However, the regimen excels in providing durable, long-term immunity for populations at ongoing risk.

Clinical trials demonstrated that primary antibody responses peak approximately 21 days following the Mvabea booster ²². The regimen is highly effective at establishing deep immunological memory. In studies where an optional subsequent Zabdeno booster was administered up to two years after the initial primary series, a powerful anamnestic (memory) response was triggered. This booster yielded EBOV GP-binding antibody concentrations roughly 40 times higher at 7 days and 110 times higher at 21 days compared to immediately pre-booster levels ⁸²¹²². Consequently, a supplementary Zabdeno booster dose is recommended for individuals at imminent risk of exposure if their primary two-dose series was completed more than four months prior ⁸²¹²³.

Regulatory Status and Market Availability The Mvabea component requires ultra-cold storage at -85°C to -55°C and possesses a 48-month shelf life under these conditions ²⁴²⁵. The combined Zabdeno/Mvabea regimen received marketing authorization under exceptional circumstances from the European Commission in July 2020 ⁷²².

However, regulatory dynamics shifted in May 2026. The European Commission officially withdrew the marketing authorization for both Zabdeno and Mvabea at the direct request of the marketing authorization holder, Janssen-Cilag International N.V. ²⁶. Janssen cited strictly commercial reasons for this withdrawal, noting that the product had not been actively marketed for commercial sale within the European Union ²⁶. Despite this regulatory withdrawal in Europe, the vaccine regimen remains prequalified by the WHO and continues to be actively procured and utilized via the Gavi-funded global stockpile for preventive vaccination campaigns in lower-risk regions across Africa ¹²²⁶²⁷.

Summary Comparison of Approved EBOV Vaccines

Global Vaccination Strategies and WHO SAGE Guidelines

The strategic deployment of Ebola vaccines has evolved significantly based on accumulating real-world data and the shifting epidemiological landscape of Sub-Saharan Africa. In July 2024, the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) issued updated, comprehensive guidelines that formally superseded the interim emergency recommendations issued in 2018 and 2019 ⁵¹⁶.

The Shift to Proactive Preventive Vaccination

Historically, Ebola vaccines were deployed almost exclusively in a reactive "ring vaccination" format during active outbreaks. Ring vaccination involves identifying a confirmed patient, tracing all of their direct contacts, identifying the contacts of those contacts, and vaccinating this entire "ring" to create a buffer of localized immunity ¹²²⁸²⁹. Approximately 350,000 individuals have been vaccinated using this strategy with Ervebo since 2016 ²⁹. While ring vaccination remains the gold standard for acute outbreak containment utilizing the rapid-acting Ervebo vaccine ²⁹, SAGE recognized a fundamental vulnerability: outbreaks are often preceded by periods of hidden, asymptomatic transmission, placing frontline health workers at extreme risk before an outbreak is formally declared ⁵¹⁶.

Consequently, the July 2024 guidelines strongly recommended the implementation of proactive, preventive vaccination programs in the absence of active outbreaks ¹⁶³⁰. SAGE advised that healthcare workers (HCWs), front-line workers (FLWs) - including traditional healers, social workers, laboratory personnel, and safe burial teams - in nations with historical EBOV outbreaks or high-risk geographical borders should be preemptively immunized ⁵¹⁶²⁷.

For these lower-risk, preventative scenarios, either Ervebo or the two-dose Zabdeno/Mvabea regimen may be utilized, though the latter is often preferred when immediate immunity is not strictly required, reserving the Ervebo supply for acute emergencies ¹²¹⁶. To support this, Gavi, the Vaccine Alliance, established a dedicated Ebola preventive vaccination program in June 2024, funding nationwide campaigns in countries like Sierra Leone and the Central African Republic ²⁷. Concurrently, a Gavi-funded global emergency stockpile, managed by the International Coordinating Group (ICG) on Vaccine Provision, maintains approximately 500,000 doses of Ervebo specifically to ensure equitable and rapid deployment within days of a new outbreak declaration ¹¹²²⁷. Between 2021 and 2023, 145,690 doses were shipped from the ICG stockpile, with 95% repurposed for preventive vaccination due to the rapid containment of smaller localized outbreaks ¹.

Inclusion of Vulnerable Populations

A critical epidemiological and ethical shift in the SAGE 2024 guidelines involves the explicit inclusion of vulnerable populations - specifically pregnant and lactating women, as well as infants and children - in vaccination protocols during active outbreaks ⁵³¹³³.

Initially, pregnant and lactating women were systematically excluded from receiving the Ervebo vaccine because it contains a live, replicating viral vector, posing theoretical risks of viremia and fetal development complications ³². However, the mortality rate of EVD in pregnant women is exceptionally high, and fetal mortality approaches 100% in infected mothers ³². Analyzing extensive post-implementation safety data from over 300,000 vaccinees in the DRC - which included 1,663 pregnant women and 6,397 infants aged 6 to 12 months - SAGE concluded that the vaccine lacks major pregnancy-related or pediatric safety concerns ¹⁶. Therefore, SAGE issued a conditional recommendation that pregnant and breastfeeding women, as well as children from birth, should be offered the Ervebo vaccine "off-label" during an active Zaire ebolavirus outbreak, provided it is administered with informed consent and within a compassionate use or rigorous research protocol ⁵²⁸³¹.

Post-Exposure Prophylaxis (PEP) Strategies

Beyond pre-exposure prevention and active outbreak ring vaccination, there is an urgent clinical need for reliable Post-Exposure Prophylaxis (PEP) protocols. The fundamental premise of PEP in the context of Ebola is to intervene during the asymptomatic incubation period of the virus - which spans from 2 to 21 days - to halt viral replication before the onset of systemic hemorrhagic disease ⁶. An effective PEP strategy is theorized to not only save the exposed individual but also drastically reduce secondary attack rates, effectively severing transmission chains and preventing nosocomial spread within healthcare facilities ⁶.

Currently, there is no single, universally approved comprehensive PEP protocol ⁶. In practice, the Ervebo vaccine is often administered off-label as a form of PEP during epidemics to exposed contacts, leveraging its rapid onset of active immunity ⁶. Furthermore, monoclonal antibodies (mAbs) have been administered compassionately as PEP to healthcare workers following high-risk occupational exposures (such as needle-stick injuries while treating EVD patients) and to neonates born to EVD-infected mothers, ideally within seven days of birth ⁶.

The EBO-PEP Clinical Trial Framework

To rigorously define an optimal, standardized PEP protocol, the multi-center, phase III EBO-PEP clinical trial (NCT06841614) was established by the ANRS Emerging Infectious Diseases agency ⁶. Designed to operate strictly during active EVD outbreaks in Sub-Saharan Africa, the trial evaluates the strategic integration of both vaccination and monoclonal antibody immunotherapy to provide both immediate viral neutralization and long-term immunological memory ⁶³³.

The trial aims to recruit asymptomatic individuals classified as high-risk contacts of confirmed cases. Participants are randomized in a 1:1 ratio into two distinct parallel arms: 1. Arm 1 (Control - ERV): Participants receive a standard single intramuscular dose of the Ervebo vaccine (72 million PFU) on Day 0 ⁶. 2. Arm 2 (Experimental Intervention - ERV+IMZ): Participants receive the Ervebo vaccine on Day 0, administered concurrently with an intravenous infusion of the monoclonal antibody Inmazeb (150 mg/kg) ⁶. To address the potential immunological interference where the infused mAbs might neutralize the live rVSV vaccine vector before it can stimulate host immunity, a revaccination booster dose of Ervebo is administered on Day 56 ⁶.

The strategic integration of mAbs in Arm 2 aims to provide immediate passive immunity, directly binding and clearing the virus during the narrow incubation window, while the delayed secondary vaccine dose ensures durable active immunity, ultimately curtailing outbreak propagation ⁶³³.

Investigational Prophylaxis for Sudan and Bundibugyo Viruses

While the prophylactic landscape for Zaire ebolavirus is maturing, a critical vulnerability exists regarding other highly pathogenic Orthoebolavirus species, particularly the Sudan ebolavirus (SUDV) and Bundibugyo ebolavirus (BDBV) ²⁵. The Ervebo and Zabdeno/Mvabea vaccines are highly specific to the Zaire glycoprotein and do not confer cross-protection against SUDV or BDBV ²⁰³⁴³⁷. Fatality rates for past SUDV outbreaks have ranged from 41% to 100%, and up to 40% for BDBV, underscoring the urgent need for expanded medical countermeasures ³³⁵.

Chimpanzee Adenovirus Vector Vaccines (cAd3)

To address this gap, the Sabin Vaccine Institute is advancing a robust research and development program focusing on monovalent vaccines for both SUDV and Marburg virus (MARV) ³³⁶³⁷.

The Sabin candidates - cAd3-Sudan Ebolavirus Vaccine and cAd3-Marburg Vaccine - are built upon a proprietary chimpanzee adenovirus type 3 (cAd3) platform ³³⁷. This platform was originally developed collaboratively by the U.S. National Institute of Allergy and Infectious Diseases' Vaccine Research Center and Okairos (which was acquired by GSK in 2013, before GSK licensed the technology exclusively to Sabin in 2019) ³⁷. The cAd3 vector is replication-deficient and is genetically modified to express the specific filovirus glycoprotein ³. Utilizing a chimpanzee adenovirus vector strategically circumvents the issue of pre-existing immunity to human adenoviruses (which circulate widely as common colds), a phenomenon that can sometimes blunt the efficacy of human adenovirus vectors like Ad26 ⁸.

Clinical Trial Status and Progression By March 2026, the Sabin Vaccine Institute had successfully completed enrollment for all six Phase 2 clinical trials assessing the safety, tolerability, and immunogenicity of the cAd3-Sudan and cAd3-Marburg vaccines ³³⁶. These trials, supported by approximately $216 million in multi-year contract awards from the U.S. Biomedical Advanced Research and Development Authority (BARDA), enrolled healthy volunteers across the United States, Kenya (at the Kenya Medical Research Institute in Siaya), and Uganda (in partnership with the Makerere University Walter Reed Project in Kampala) ³⁶⁴¹.

Collectively, over 2,800 participants have received doses across both candidate programs ³⁶³⁸. Phase 1 and interim Phase 2 results indicate that the single-dose cAd3 vaccines are well-tolerated, with no significant safety concerns reported, and elicit rapid, robust immune responses that endure for up to 12 months ³⁶⁴¹³⁸. Notably, the cAd3-Marburg candidate was deployed in rapid-response outbreak clinical trials during Marburg outbreaks in Rwanda (2024, enrolling 1,700 participants) and Ethiopia (2025, enrolling 500 participants), demonstrating the operational viability of deploying these investigational products in acute humanitarian emergencies ³⁶. However, as of mid-2026, there are no licensed vaccines for SUDV or BDBV available outside of clinical trial frameworks, leaving populations vulnerable to sudden emergence events ³.

Therapeutics and Optimized Supportive Care as Secondary Prevention

In the clinical management of EVD, therapeutics act as a vital form of secondary prevention. Effective treatment not only prevents the progression of the infection to severe multi-organ failure and death in the individual patient but also reduces viral shedding, thereby protecting healthcare workers and the broader community from nosocomial transmission ². For decades following the discovery of the virus in 1976, the cornerstone of EVD treatment was purely supportive, with fatality rates remaining devastatingly high ⁴.

Optimized Supportive Care (OSC) Protocols

EVD pathophysiology involves profound gastrointestinal fluid loss through severe diarrhea and vomiting, which rapidly leads to hypovolemic shock, critical electrolyte derangements, acute kidney injury, and disseminated intravascular coagulation ¹¹⁴³. Optimized Supportive Care (OSC) is a highly standardized protocol involving aggressive oral or intravenous rehydration, electrolyte repletion, maintenance of blood pressure utilizing vasopressors if necessary, oxygenation, pain management, and the prompt treatment of secondary bacterial infections and pre-existing comorbidities such as malaria ¹¹⁴³³⁹.

Rigorous implementation of OSC significantly improves survival probabilities. In a pivotal 2014 study published in the New England Journal of Medicine analyzing 37 EVD patients in Guinea, the application of aggressive intravenous fluid resuscitation and metabolic correction lowered the fatality rate to 43% ⁴³. This was a significant improvement compared to the 74% fatality rate observed in contemporary treatment centers in Sierra Leone that lacked the resources to provide advanced supportive care ⁴³. The WHO mandates that OSC is the essential baseline care that all Ebola patients must receive, regardless of the availability of specific antiviral therapeutics ²³⁹⁴⁰.

Monoclonal Antibody Therapeutics (mAbs)

The therapeutic paradigm for Zaire ebolavirus shifted dramatically following the results of the Pamoja Tulinde Maisha (PALM) randomized controlled trial, conducted during the complex 2018 - 2020 North Kivu and Ituri epidemic in the DRC ⁴⁴⁰. The trial aimed to compare four investigational therapies: the antiviral remdesivir, the mAb cocktail ZMapp (serving as the control arm based on previous promise), a single mAb named mAb114 (Ebanga), and a triple-mAb cocktail named REGN-EB3 (Inmazeb) ⁴⁴¹.

Enrolling 681 patients with laboratory-confirmed EVD, the PALM trial yielded definitive results demonstrating the clinical superiority of Ebanga and Inmazeb over both ZMapp and remdesivir in reducing 28-day mortality ⁴⁴¹.

• Inmazeb (REGN-EB3): Developed by Regeneron, this is a cocktail of three neutralizing humanized mAbs (atoltivimab, maftivimab, and odesivimab) that target distinct epitopes on the EBOV glycoprotein, preventing viral entry into host cells ⁶¹¹. In the PALM trial, mortality in the REGN-EB3 group was significantly reduced to 33.5%, compared to 51.3% in the ZMapp control group ⁴¹.
• Ebanga (mAb114): A single mAb derived from the memory B cells of a survivor of the 1995 Kikwit EVD outbreak ⁴. It binds the EBOV surface glycoprotein, impeding viral entry and initiating antibody-dependent cellular cytotoxicity (ADCC) ⁴. Mortality in the Ebanga group was 35.1%, compared to 49.7% in the ZMapp group ⁴¹.

Based on these compelling findings, the U.S. FDA approved both Inmazeb and Ebanga in 2020 for the treatment of EVD in adults and children, including neonates ⁴⁶¹¹. Subsequently, in August 2022, the WHO published its first formal therapeutic guidelines for EVD, issuing strong recommendations for the use of either Inmazeb or Ebanga as the standard of care, and explicitly advising against the use of ZMapp and remdesivir for this indication ⁴⁰. It is critical to note that the efficacy of these mAbs is highly specific to the Zaire species; they offer no therapeutic benefit for infections caused by SUDV or BDBV ¹¹³⁹.

Infection Prevention and Control (IPC) and Socio-Cultural Adaptations

In the absence of universally available vaccines, or when confronting viral species for which specific medical countermeasures do not exist, meticulous Infection Prevention and Control (IPC) protocols remain the primary bulwark against EVD transmission ²³⁴. The virus is not airborne; it spreads through direct contact with the blood, vomit, feces, and other bodily fluids of symptomatic patients, or through contact with contaminated fomites (such as bedding, clothing, or medical equipment) ²⁵³⁴.

Clinical IPC Measures

In healthcare settings, the risk of nosocomial transmission to healthcare workers is extreme. Strict IPC guidelines mandate the use of comprehensive Personal Protective Equipment (PPE) designed to block splashes and skin contact ²³⁴. Suspected or confirmed EVD cases must be placed in private isolation rooms with dedicated bathroom facilities or covered bedside toilets ³⁴. Furthermore, routine diagnostic laboratory testing for differential diagnoses (such as malaria or influenza-like illnesses) must proceed with heightened biosafety measures, as drawing and processing blood from an unrecognized EVD patient poses a lethal biohazard risk to laboratory personnel ²¹¹³⁴.

Safe and Dignified Burials (SDB)

A disproportionate number of community transmission chains in historical EVD outbreaks have been directly traced to traditional funeral and burial practices ⁴²⁴³. In many central and western African communities, traditional mourning involves washing, touching, and dressing the deceased - actions that pose catastrophic risks, as viral loads in body fluids remain exceptionally high immediately following death, and the virus can persist on the corpse for days ⁴²⁴³.

To mitigate this vector of transmission, global health authorities deploy highly regulated Safe and Dignified Burial (SDB) protocols ⁴²⁴⁴. However, aggressive enforcement of sterile, medicalized burials by foreign or unknown teams during past outbreaks frequently triggered intense community resistance, leading to attacks on response teams and the secret, unsafe burial of EVD victims by fearful families ⁴³⁴⁴. Modern SDB protocols have therefore been extensively adapted to integrate socio-cultural and religious sensitivities without compromising epidemiological safety ⁴²⁴⁵.

Key socio-cultural adaptations include: * Community Integration: SDB teams are encouraged to recruit and train local community members to act as liaisons, ensuring the burial team is not entirely composed of outsiders, thereby building trust ⁴³. * Transparent Processes: The family must be engaged and give formal agreement before any burial procedure begins. Crucially, SDB teams arrive at the home without wearing PPE to greet the family and offer condolences before donning protective gear in a designated safe zone ⁴⁴⁴⁵. * Religious Accommodation: Protocols are specifically adapted for diverse faiths. For Muslim patients, permission is sought from an Imam to use a white body bag to represent the traditional shroud, and a Muslim faith representative is permitted to recite a short Arabic prayer of intention over the deceased from a safe distance ⁴³⁴⁴. For Christian patients, families are permitted to identify specific items to be buried with the deceased (handled by the trained team) and may throw the first soil onto the grave ⁴⁴. * Visual Contact: Enabling family members to safely "see the dead" is prioritized. While touching is forbidden, transparent face-panels on body bags are often utilized, allowing psychological closure without tactile exposure ⁴²⁴³.

Despite the existence of these optimized protocols, implementing IPC in rural, under-resourced, or conflict-affected environments remains highly challenging. Research following the 2022 - 2023 Uganda outbreaks highlighted recurring barriers to IPC compliance, including delayed consultations with communities, contradictory public messaging, language barriers, and a critical lack of protective logistics and compensation for local community health workers volunteering in the response ⁴⁶.

Case Study: The 2026 Bundibugyo Ebolavirus Crisis

The critical reliance on comprehensive IPC, optimized supportive care, and regional coordination is currently being stress-tested by a severe, multi-national outbreak occurring in May 2026. This crisis vividly illustrates the systemic vulnerabilities that persist when medical countermeasures for non-Zaire strains are lacking.

Epidemiological Escalation and Emergency Declarations

In early May 2026, the WHO was alerted to a high-mortality cluster of an unknown illness - including the rapid deaths of four healthcare workers - in the Mongbwalu Health Zone of the Ituri Province, DRC ⁴⁷. On May 14, 2026, laboratory analysis by the Institut National de Recherche Biomédicale (INRB) in Kinshasa confirmed that the causative agent was the Bundibugyo ebolavirus (BDBV) ³⁷⁴⁷. Concurrently, the Uganda Ministry of Health confirmed an imported fatal case of BDBV in a 59-year-old Congolese male who had traveled to the capital city of Kampala ⁴⁷⁴⁸.

By mid-May 2026, the epidemiological situation had deteriorated rapidly in a complex humanitarian context. A critical four-week detection gap between the presumed index case in April and the laboratory confirmation in May allowed widespread, unchecked community transmission, exacerbated by unsafe burial practices and critical breaches in clinical IPC protocols ⁴⁷. The Ituri province is characterized by armed conflict, 273,000 internally displaced persons, intense cross-border mining traffic, and weak local health infrastructure ⁴⁷⁴⁹. Provisional data cited approximately 395 suspected cases and 106 deaths across the region ⁴⁹.

Recognizing the imminent threat of regional exportation and the lack of specific medical countermeasures for the Bundibugyo strain, the Africa Centres for Disease Control and Prevention (Africa CDC), acting on the advice of its Emergency Consultative Group, officially declared the outbreak a Public Health Emergency of Continental Security (PHECS) on May 18, 2026 ⁴⁹. This was immediately preceded by the WHO Director-General declaring the event a Public Health Emergency of International Concern (PHEIC) on May 16, 2026, under the International Health Regulations ⁴⁷⁵⁰.

Coordinated Continental Response and IMST Pillars

Because the approved Ervebo vaccine and the Inmazeb/Ebanga therapeutics are strictly effective against Zaire ebolavirus and offer no protection against BDBV, the response strategy cannot rely on pharmaceutical interventions ³⁵⁴⁷. Instead, it relies heavily on classical epidemiological containment and rapid operational research ³⁵⁴⁷⁴⁹.

Africa CDC and the WHO activated a joint Incident Management Support Team (IMST) to coordinate a multi-national response encompassing the DRC, Uganda, and neighboring South Sudan, operating under the "4 Ones" principle: one team, one plan, one budget, and one monitoring framework ⁴⁸⁴⁹⁵¹.

The primary response pillars implemented by the IMST include: 1. Surveillance and Decentralized Diagnostics: Establishing dedicated surveillance cells for contact tracing in highly mobile mining areas and decentralizing laboratory capacity to rapidly sequence and test for BDBV at the sub-national level ⁵⁰⁵². 2. Enhanced IPC and SDB: Deploying expert multidisciplinary surge teams to address the critical breaches in infection control that led to healthcare worker fatalities in Mongbwalu, and ensuring SDB teams have the training and resources to conduct culturally adapted burials ³⁷⁴⁷⁴⁸. 3. Medical Countermeasure Escalation: The WHO Technical Advisory Group and the Africa CDC Science, Innovation, and R&D teams were immediately convened to assess product options ³⁵⁴⁸. They evaluated whether any existing stockpiled vaccines could be deployed under an experimental clinical trial framework (based on limited animal models suggesting minor cross-protection) and sought to accelerate the development of BDBV-specific diagnostics and therapeutics ^35484953. 4. Cross-Border Coordination: Implementing stringent screening at Points of Entry (PoE) and aligning data management, contact tracing, and risk communication across the DRC-Uganda-South Sudan borders to prevent further international spread ⁴⁷⁴⁸⁵¹.

The political response has also emphasized African sovereignty. Following the U.S. issuance of a Level 4 "Do Not Travel" advisory for the region, Africa CDC pushed back, advocating for a "Team Africa" approach that prioritizes solidarity and investment over economic isolation, noting that travel bans often cause economic damage without delivering proportional public health benefits ⁵³.

The 2026 Bundibugyo outbreak vividly illustrates that while medical science has achieved remarkable success in conquering Zaire ebolavirus, achieving comprehensive global health security against the entire Orthoebolavirus genus requires sustained investment in multi-strain vaccine platforms, decentralized diagnostic capabilities, and robust, community-led infection prevention frameworks that function effectively outside of the laboratory.